|

ORIENT-31 regimen Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Fudan University1

Indications

  • EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer1
  • NSCLC (Advanced Non-small Cell Lung Cancer)1
  • Lung Cancer1
  • Cancer1

Other1 trial

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.